The role of hyperleptinaemia and low values of interleukin 10 in de novo DSA production after kidney transplantation

被引:0
|
作者
Dedinska, Ivana [1 ,2 ,3 ,5 ]
Kleinova, Patricia [1 ,2 ,3 ]
Machalekova, Katarina [4 ]
Granak, Karol [1 ,2 ,3 ]
Vnucak, Matej [1 ,2 ,3 ]
Beliancinova, Monika [1 ,2 ,3 ]
机构
[1] Univ Hosp Martin, Transplant Ctr, Martin, Slovakia
[2] Comenius Univ, Jessenius Fac Med, Bratislava, Slovakia
[3] Univ Hosp Martin, Dept Internal Dis 1, Martin, Slovakia
[4] St Elizabeth Canc Inst, Dept Pathol, Bratislava, Slovakia
[5] Univ Hosp Martin, Transplant Ctr, Kollarova 2, Martin 03601, Slovakia
关键词
Leptin; IL-10; Protocol biopsy; Kidney transplantation; LEPTIN LEVELS; BODY-FAT; POLYMORPHISMS; ADIPONECTIN; ACTIVATION; DISEASE; WEIGHT; IL-10; ALPHA; INDEX;
D O I
10.1016/j.trim.2023.101982
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: White adipose tissue secretes a number of peptide hormones. The aim of this paper was to determine the role of leptin, adiponectin and interleukin-10 and interleukin-6 on the development of graft rejection in protocol biopsy after kidney transplantation. Methods: In a prospective analysis (n = 104), we monitored the values of leptin, adiponectin, IL -6, and IL -10 prior to the transplantation and in the 3rd month after the transplantation. The protocol biopsy of the graft was performed in the 3rd month after the transplantation. The group was divided into the following according to the biopsy result: negative result, IFTA 1, borderline, and DSA positive. Results: After adjusting for the differences in the baseline recipient and donor characteristics, we identified the hyperleptinaemia baseline (HR = 2.0444, P = 0.0341) and month 3 (HR = 49.8043, P < 0.0001) as independent risk factors for borderline changes in the protocol biopsy. The hyperleptinaemia baseline (HR = 7.4979, P = 0.0071) and month 3 (HR = 9.7432, P = 0.0057) are independent risk factors for de novo DSA positivity. A low value of IL -10 month 3 is a risk factor for de novo DSA positivity (HR = 3.0746, P = 0.0388). Conclusions: Higher leptin levels and low values of IL -10 might play a role in rejection and de novo DSA production.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results
    Russ, G. R.
    Tedesco-Silva, H.
    Kuypers, D. R.
    Cohney, S.
    Langer, R. M.
    Witzke, O.
    Eris, J.
    Sommerer, C.
    von Zur-Muehlen, B.
    Woodle, E. S.
    Gill, J.
    Ng, J.
    Klupp, J.
    Chodoff, L.
    Budde, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (07) : 1746 - 1756
  • [32] Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange
    Sagmeister, Michael S.
    Weiss, Max
    Eichhorn, Peter
    Habicht, Antje
    Habersetzer, Rupert
    Fischereder, Michael
    Schoenermarck, Ulf
    BMC NEPHROLOGY, 2018, 19
  • [33] Successful treatment of de novo thrombotic microangiopathy after minor ABO-mismatched living donor kidney transplantation
    Ushigome, Hidetaka
    Sakai, Kazuki
    Suzuki, Tomoyuki
    Nobori, Syuji
    Yoshizawa, Atsushi
    Kaihara, Satoshi
    Okamoto, Masahiko
    Urasaki, Koji
    Yoshimura, Norio
    CLINICAL TRANSPLANTATION, 2008, 22 : 25 - 30
  • [34] Characteristics and Clinical Significance of De Novo Donor-Specfic Anti-HLA Antibodies after Kidney Transplantation
    Jung, Hee-Yeon
    Kim, Su-Hee
    Seo, Min-Young
    Cho, Sun-Young
    Yang, Youngae
    Choi, Ji-Young
    Cho, Jang-Hee
    Park, Sun-Hee
    Kim, Yong-Lim
    Kim, Hyung-Kee
    Huh, Seung
    Won, Dong Il
    Kim, Chan-Duck
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, 33 (34)
  • [35] Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange
    Michael S. Sagmeister
    Max Weiss
    Peter Eichhorn
    Antje Habicht
    Rupert Habersetzer
    Michael Fischereder
    Ulf Schönermarck
    BMC Nephrology, 19
  • [36] Role of cytomegalovirus and Epstein-Barr virus in patients with de novo colon cancer after renal transplantation
    Adani, Gian Luigi
    Baccarani, Umberto
    Lorenzin, Dario
    Bresadola, Vittorio
    Curro, Giuseppe
    Sainz, Mauricio
    Gropuzzo, Maria
    Montanaro, Domenico
    Tulissi, Patrizia
    Risaliti, Andrea
    Bresadola, Fabrizio
    TUMORI JOURNAL, 2006, 92 (03): : 219 - 221
  • [37] Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study
    De Meyer, Martine
    Haufroid, Vincent
    Kanaan, Nada
    Darius, Tom
    Buemi, Antoine
    De Pauw, Luc
    Eddour, Djamila Chaib
    Wallemacq, Pierre
    Mourad, Michel
    PHARMACOGENOMICS, 2016, 17 (09) : 1019 - 1027
  • [38] A case of recurrent proliferative glomerulonephritis with monoclonal IgG deposits or de novo C3 glomerulonephritis after kidney transplantation
    Tamura, Tomomi
    Unagami, Kohei
    Okumi, Masayoshi
    Kakuta, Yoichi
    Horita, Shigeru
    Ishida, Hideki
    Koike, Junki
    Honda, Kazuho
    Tanabe, Kazunari
    Nitta, Kosaku
    NEPHROLOGY, 2018, 23 : 76 - 80
  • [39] Evaluation of Cumulative Effect of Standard Triple Immunosuppression on Prevention of De Novo Donor Specific Antibodies (dnDSA) Production in Children after Kidney Transplantation-A Retrospective and Prospective Study
    Urzykowska, Agnieszka
    Piatosa, Barbara
    Grycuk, Urszula
    Kowalewski, Grzegorz
    Kulaga, Zbigniew
    Grenda, Ryszard
    CHILDREN-BASEL, 2021, 8 (12):
  • [40] De novo posttransplant membranous nephropathy after COVID-19 vaccination 9 years after renal transplantation in a patient with polycystic kidney disease
    Fukuda, Miruzato
    Yokoyama, Takayoshi
    Miki, Katsuyuki
    Yamanouchi, Masayuki
    Ikuma, Daisuke
    Mizuno, Hiroki
    Oba, Yuki
    Inoue, Noriko
    Sekine, Akinari
    Tanaka, Kiho
    Hasegawa, Eiko
    Suwabe, Tatsuya
    Wada, Takehiko
    Kono, Kei
    Kinowaki, Keiichi
    Ohashi, Kenichi
    Yamaguchi, Yutaka
    Nakamura, Yuki
    Ishii, Yasuo
    Sawa, Naoki
    Ubara, Yoshifumi
    CEN CASE REPORTS, 2024, 13 (06) : 434 - 439